During the past decade, University Diabetes & Endocrine Consultants conducted 21 clinical trials. In the 10-year time frame, 21 clinical trials started and 16 clinical trials were completed, i.e. on average, 76.2% percent of trials that started reached the finish line to date. In the past 5 years, 7 clinical trials started and 10 clinical trials were completed. i.e. 142.9% of trials that started reached the finish line.

Out of the total clinical trials conducted in "University Diabetes & Endocrine Consultants" #1 sponsor was "Eli Lilly and Company" with 6 trials, followed by "Gan and Lee Pharmaceuticals, USA" with 3 trials sponsored, "Boehringer Ingelheim" with 2 trials sponsored, "MacroGenics" with 2 trials sponsored and "Marius Pharmaceuticals" with 2 trials sponsored. Other sponsors include 9 different institutions and companies that sponsored additional 19 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "University Diabetes & Endocrine Consultants" #1 collaborator was "Eli Lilly and Company" with 4 trials as a collaborator, "Syneos Health" with 2 trials as a collaborator, "AbCellera Biologics Inc." with 1 trials as a collaborator, "Amylin Pharmaceuticals, LLC." with 1 trials as a collaborator and "Boehringer Ingelheim" with 1 trials as a collaborator. Other collaborators include 4 different institutions and companies that were collaborators in the rest 14 trials.

According to Clinical.Site data, the most researched conditions in "University Diabetes & Endocrine Consultants" are "Diabetes Mellitus, Type 2" (7 trials), "Diabetes Mellitus, Type 1" (5 trials), "Type 1 Diabetes Mellitus" (4 trials), "Diabetic Kidney Disease" (2 trials) and "Hypogonadism, Male" (2 trials). Many other conditions were trialed in "University Diabetes & Endocrine Consultants" in a lesser frequency.

Most popular intervention types in "University Diabetes & Endocrine Consultants" are "Drug" (23 trials), "Biological" (4 trials), "Device" (3 trials) and "Other" (3 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (13 trials), "Gan & Lee Insulin Glargine Injection" (2 trials), "Insulin Degludec" (2 trials), "Lantus®" (2 trials) and "SOV2012-F1" (2 trials). Other intervention names were less common.

The vast majority of trials in "University Diabetes & Endocrine Consultants" are 27 trials for "All" genders and 2 trials for "Male" genders.

Currently, there are NaN active trials in "University Diabetes & Endocrine Consultants". undefined are not yet recruiting, 1 are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 23 completed trials in University Diabetes & Endocrine Consultants, undefined suspended trials, and 3 terminated clinical trials to date.

Out of the total trials that were conducted in University Diabetes & Endocrine Consultants, 1 "Phase 1" clinical trials were conducted, 11 "Phase 2" clinical trials and 16 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 2 trials that are defined as “Not Applicable".